Display options
Cite
Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology. 2017;6(4):e1295202doi: 10.1080/2162402X.2017.1295202.
Nijland, M., Veenstra, R. N., Visser, L., Xu, C., Kushekhar, K., van Imhoff, G. W., Kluin, P. M., van den Berg, A., & Diepstra, A. (2017). HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology, 6(4), e1295202. https://doi.org/10.1080/2162402X.2017.1295202
Nijland, Marcel, et al. "HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?." Oncoimmunology vol. 6,4 (2017): e1295202. doi: https://doi.org/10.1080/2162402X.2017.1295202
Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology. 2017 Mar 03;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017. PMID: 28507804; PMCID: PMC5414870.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2017 Mar 03;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017.

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?.

Oncoimmunology

Marcel Nijland, Rianne N Veenstra, Lydia Visser, Chuanhui Xu, Kushi Kushekhar, Gustaaf W van Imhoff, Philip M Kluin, Anke van den Berg, Arjan Diepstra

Affiliations

  1. Department of Hematology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  2. Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

PMID: 28507804 PMCID: PMC5414870 DOI: 10.1080/2162402X.2017.1295202

Abstract

Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389 classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin lymphomas (NLPHL), 137 diffuse large B-cell lymphomas (DLBCL), 39 primary central nervous system lymphomas (PCNSL) and 19 testicular lymphomas. We describe a novel mechanism of immune escape in which loss of HLA-DM expression results in aberrant membranous invariant chain peptide (CLIP) expression in HLA class II cell surface positive lymphoma cells, preventing presentation of antigenic peptides. In HLA class II positive cases, HLA-DM expression was lost in 49% of cHL, 0% of NLPHL, 14% of DLBCL, 3% of PCNSL and 0% of testicular lymphomas. Considering HLA class I, HLA class II and HLA-DM together, 88% of cHL, 10% of NLPHL, 62% of DLBCL, 77% of PCNSL and 87% of testicular lymphoma cases had abnormal HLA expression patterns. In conclusion, an HLA expression pattern incompatible with normal antigen presentation is common in cHL, DLBCL, PCNSL and testicular lymphoma. Retention of CLIP in HLA class II caused by loss of HLA-DM is a novel immune escape mechanism, especially prevalent in cHL. Aberrant HLA expression should be taken into account when evaluating efficacy of checkpoint inhibitors in B-cell lymphomas.

Keywords: Diffuse large B-cell lymphoma; Epstein barr virus; Hodgkin lymphoma; human leukocyte antigen; immune checkpoint inhibitor; immune evasion; major histocompatibility complex; primary central nervous system lymphoma; therapy response

References

  1. Blood. 1998 Oct 1;92(7):2252-9 - PubMed
  2. J Clin Oncol. 2016 Aug 10;34(23):2698-704 - PubMed
  3. Semin Cancer Biol. 2014 Feb;24:15-22 - PubMed
  4. Cell Rep. 2015 Nov 17;13(7):1418-31 - PubMed
  5. Nat Rev Immunol. 2011 Nov 11;11(12):823-36 - PubMed
  6. Immunology. 2009 Sep;128(1 Suppl):e641-51 - PubMed
  7. Leukemia. 1993 Mar;7(3):398-403 - PubMed
  8. Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 - PubMed
  9. Nat Rev Clin Oncol. 2016 May;13(5):273-90 - PubMed
  10. J Pathol. 2005 Jul;206(3):328-36 - PubMed
  11. Nat Rev Clin Oncol. 2016 Jan;13(1):25-40 - PubMed
  12. Blood. 2011 Jun 30;117(26):7070-8 - PubMed
  13. Virchows Arch. 2017 Jan;470(1):113-117 - PubMed
  14. Blood. 2006 Feb 1;107(3):1101-7 - PubMed
  15. Clin Cancer Res. 2009 Oct 15;15(20):6446-53 - PubMed
  16. Exp Hematol. 2009 Feb;37(2):184-194 - PubMed
  17. J Clin Oncol. 2013 Nov 20;31(33):4199-206 - PubMed
  18. Nat Genet. 2011 Jul 31;43(9):830-7 - PubMed
  19. Blood. 2004 Jun 1;103(11):4251-8 - PubMed
  20. Blood. 1998 Oct 1 ;92 (7):2477-83 - PubMed
  21. Nat Immunol. 2004 Sep;5(9):909-18 - PubMed
  22. Blood. 1998 Aug 1;92 (3):1020-30 - PubMed
  23. Br J Haematol. 2002 Nov;119(2):417-24 - PubMed
  24. N Engl J Med. 2015 Jan 22;372(4):311-9 - PubMed
  25. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84 - PubMed
  26. Cancers (Basel). 2015 Apr 30;7(2):736-62 - PubMed
  27. Blood. 2000 Nov 15;96(10):3569-77 - PubMed
  28. Cancer. 1990 Sep 15;66(6):1147-53 - PubMed
  29. J Clin Oncol. 2007 Jul 20;25(21):3101-8 - PubMed
  30. Cancer Cell. 2011 Dec 13;20(6):728-40 - PubMed
  31. Leukemia. 2004 Mar;18(3):589-96 - PubMed
  32. Blood. 2013 Aug 15;122(7):1256-65 - PubMed
  33. Haematologica. 2009 Apr;94(4):596-8 - PubMed
  34. Nature. 2011 Mar 17;471(7338):377-81 - PubMed
  35. Leukemia. 2014 Nov;28(11):2248-51 - PubMed
  36. Blood. 2006 Jul 1;108(1):311-8 - PubMed
  37. Proc Natl Acad Sci U S A. 1989 Jan;86(1):282-6 - PubMed
  38. Blood. 2015 Feb 12;125(7):1061-72 - PubMed
  39. Haematologica. 2009 Nov;94(11):1569-80 - PubMed
  40. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398-403 - PubMed
  41. Blood. 2012 Feb 9;119(6):1459-67 - PubMed
  42. Nat Immunol. 2000 Dec;1(6):526-32 - PubMed
  43. Nat Commun. 2016 Jan 29;7:10582 - PubMed
  44. Nat Rev Clin Oncol. 2014 Jan;11(1):24-37 - PubMed
  45. Blood. 1996 May 1;87(9):3844-51 - PubMed
  46. Nature. 2011 Jul 27;476(7360):298-303 - PubMed
  47. Leuk Lymphoma. 2009 Nov;50(11):1875-8 - PubMed

Publication Types